■疫苗临床试验应努力招募种族,社会经济,以及不同种族的参与者,以确保与人口特征相匹配的适当代表。然而,研究的全面纳入往往是有限的。
■对布莱根妇女医院(波士顿,MA)在2020年7月至2021年12月之间。人口特征,包括年龄,种族,种族,邮政编码,和出生时分配的性别,从研究期间的HIV和COVID-19疫苗试验中进行了分析,承认在这些参数下对表示的限制。我们将疫苗试验参与者的教育程度与马萨诸塞州都会区的居民进行了比较,地理编码参与者的地址到他们的人口普查区块组,并将其与2020年公开数据中报告的家庭收入中位数水平联系起来。进行了频率和四分位数分析,和空间分析使用ArcGIS在线基于网络的制图软件(Esri)进行。
■共有来自四项COVID-19疫苗试验(n=916名参与者)和六项HIV疫苗试验(n=114名参与者)的1030名参与者被纳入分析。COVID-19和HIV疫苗试验的平均年龄为49岁(IQR33-63)和28岁(IQR24-34),分别。确认为白人的参与者是COVID-19(n=598,65.3%)和HIV疫苗试验(n=83,72.8%)的多数代表。不到25%的参与者被确定为西班牙裔或拉丁裔。根据居住的邮政编码,COVID-19疫苗临床试验参与者(n=846)的家庭收入中位数为102,088美元(IQR=81,442-126,094).对于HIV疫苗临床试验参与者(n=109),家庭收入中位数为101,266美元(IQR75,052-108,832)。
我们在一个中心描述了参加HIV和COVID-19疫苗试验的参与者的特征,并在地理分布上发现了相似之处,中位数收入,以及两种疫苗候选试验中代表性不足的个体的比例。需要进一步的外联努力,以确保纳入来自较低教育和社会经济阶层的个人。此外,必须继续和持续的努力,以确保包容来自不同种族和族裔背景的个人。
UNASSIGNED: Vaccine clinical trials should strive to recruit a racially, socioeconomically, and ethnically diverse range of participants to ensure appropriate representation that matches population characteristics. Yet, full inclusion in research is often limited.
UNASSIGNED: A single-center retrospective study was conducted of adults enrolled at Brigham and Women\'s Hospital (
Boston, MA) between July 2020 and December 2021. Demographic characteristics, including age, race, ethnicity, ZIP code, and sex assigned at birth, were analyzed from both HIV and COVID-19 vaccine trials during the study period, acknowledging the limitations to representation under these parameters. We compared the educational attainment of vaccine trial participants to residents of the Massachusetts metropolitan area, geocoded participants\' addresses to their census block group, and linked them to reported median household income levels from publicly available data for 2020. Frequency and quartile analyses were carried out, and spatial analyses were performed using ArcGIS Online web-based mapping software (Esri).
UNASSIGNED: A total of 1030 participants from four COVID-19 vaccine trials (n = 916 participants) and six HIV vaccine trials (n = 114 participants) were included in the analysis. The median age was 49 years (IQR 33-63) and 28 years (IQR 24-34) for the COVID-19 and HIV vaccine trials, respectively. Participants identifying as White were the majority group represented for both the COVID-19 (n = 598, 65.3%) and HIV vaccine trials (n = 83, 72.8%). Fewer than 25% of participants identified as Hispanic or Latin. Based on ZIP code of residence, the median household income for COVID-19 vaccine clinical trial participants (n = 846) was 102,088 USD (IQR = 81,442-126,094). For HIV vaccine clinical trial participants (n = 109), the median household income was 101,266 USD (IQR 75,052-108,832).
UNASSIGNED: We described the characteristics of participants enrolled for HIV and COVID-19 vaccine trials at a single center and found similitude in geographical distribution, median incomes, and proportion of underrepresented individuals between the two types of vaccine candidate trials. Further outreach efforts are needed to ensure the inclusion of individuals from lower educational and socioeconomic brackets. In addition, continued and sustained efforts are necessary to ensure inclusion of individuals from diverse racial and ethnic backgrounds.